
|Videos|May 12, 2016
The Long-Term Impact of Biosimilars on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Advertisement
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Round-Up: Every Most Favored Nation Agreement With the Trump Administration
2
Study Finds Persistent Gaps in Diagnoses for Depression and Chronic Conditions After COVID-19
3
Dato-DXd Granted Priority Review as First-Line Therapy for Metastatic Triple-Negative Breast Cancer
4
Q&A: Buying Smart, Not Scarce—Pharmacists at the Center of Drug Shortage Prevention
5


























